1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997. 337:898–909.
Article
2. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD. Amyloid fibril protein nomenclature -- 2002. Amyloid. 2002. 9:197–200.
3. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD. A primer of amyloid nomenclature. Amyloid. 2007. 14:179–183.
Article
4. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005. 62:1057–1062.
Article
5. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010. 52:347–361.
Article
6. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006. 166:1805–1813.
7. Rapezzi C, Perugini E, Salvi F, Grigioni F, Riva L, Cooke RM, Ferlini A, Rimessi P, Bacchi-Reggiani L, Ciliberti P, Pastorelli F, Leone O, Bartolomei I, Pinna AD, Arpesella G, Branzi A. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid. 2006. 13:143–153.
Article
8. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003. 349:583–596.
Article
9. Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc. 1984. 59:547–555.
Article
10. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005. 112:2047–2060.
Article
11. Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, Hare JM, Baughman KL, Kasper EK. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004. 43:410–415.
Article
12. Benson MD, Uemichi T. Transthyretin amyloidosis. Amyloid Int J Exp Clin Invest. 1996. 3:44–56.
Article
13. Ikeda S, Hanyu N, Hongo M, Yoshioka J, Oguchi H, Yanagisawa N, Kobayashi T, Tsukagoshi H, Ito N, Yokota T. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain. 1987. 110(Pt 2):315–337.
Article
14. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007. 36:411–423.
Article
15. Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve. 2007. 35:116–118.
Article
16. Bittencourt PL, Couto CA, Clemente C, Farias AQ, Palácios SA, Mies S, Goldberg AC. Phenotypic expression of familial amyloid polyneuropathy in Brazil. Eur J Neurol. 2005. 12:289–293.
Article
17. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology. 2002. 58:1001–1007.
Article
18. Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranløv PJ. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med. 2003. 254:225–235.
Article
19. Yazak M, Take YI, Katoh M, Ikeda SI. Postmortem findings in two familial amyloidosis patients with transthyretin variant Asp38Ala. Amyloid. 2000. 7:270–277.
Article
20. Tachibana N, Tokuda T, Yoshida K, Taketomi T, Nakazato M, Li YF, Masuda Y, Ikeda S. Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid. 1999. 6:282–288.
Article
21. Kishikawa M, Nakanishi T, Miyazaki A, Shimizu A, Kusaka H, Fukui M, Nishiue T. A new amyloidogenic transthyretin variant, [D38A], detected by electrospray ionization/mass spectrometry. Amyloid. 1999. 6:278–281.
Article